financetom
Business
financetom
/
Business
/
US FDA extends review of GSK's blood cancer drug
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US FDA extends review of GSK's blood cancer drug
Jul 23, 2025 9:23 AM

July 23 (Reuters) - The U.S. Food and Drug

Administration has extended its review of GSK's blood

cancer drug Blenrep as a combination treatment, the company said

on Wednesday.

The health regulator has set an action date of October 23

which provides the FDA with time to review additional

information provided in support of the application.

(Reporting by Sneha S K and Sriparna Roy in Bengaluru; Editing

by Sriraj Kalluvila)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Waters raises lower end of 2025 profit forecast on demand for lab equipment
Waters raises lower end of 2025 profit forecast on demand for lab equipment
Aug 4, 2025
(Reuters) -Lab equipment maker Waters raised the lower end of its annual profit forecast on Monday after reporting better-than-expected second-quarter results on improved demand from biotech clients for its tools used in drug development and research. Shares of the Milford, Massachusetts-based company were up 3.7% premarket in low trading volumes. The company supplies lab equipment and technology across the world,...
Waters raises lower end of 2025 profit forecast on demand for lab equipment
Waters raises lower end of 2025 profit forecast on demand for lab equipment
Aug 4, 2025
Aug 4 (Reuters) - Lab equipment maker Waters raised the lower end of its annual profit forecast on Monday after reporting better-than-expected second-quarter results on improved demand from biotech clients for its tools used in drug development and research. Shares of the Milford, Massachusetts-based company were up 3.7% premarket in low trading volumes. The company supplies lab equipment and technology...
Warburg Pincus-backed Miami International eyes up to $1.7 billion valuation in US IPO
Warburg Pincus-backed Miami International eyes up to $1.7 billion valuation in US IPO
Aug 4, 2025
Aug 4 (Reuters) - Miami International Holdings, the parent of bourse operator MIAX, said on Monday it was targeting a valuation of up to $1.67 billion in its New York initial public offering. The Princeton, New Jersey-based company, backed by private equity firm Warburg Pincus, is seeking to raise up to $315 million by offering 15 million shares priced between...
Copyright 2023-2026 - www.financetom.com All Rights Reserved